3 completed, 2 active not recruiting, 1 terminated, 1 withdrawn. 4 Phase 1, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
| Phase 3 | 2 | Active not recruiting 2 |
| Phase 2 | 1 | Terminated 1 |
Follow emactuzumab: new trials by email Literature Review of emactuzumab trials Research Report on emactuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) Emactuzumab, Placebo - TGCT | Phase 3 | Active not recruiting | SynOx Therapeutics Limited | 128 | 2024-10-09 | 2026-07-29 |
| A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study Atezolizumab, Bevacizumab, Alectinib - Cancer | Phase 3 | Active not recruiting | Hoffmann-La Roche | 1000 | 2019-02-28 | 2026-10-22 |
| A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Atezolizumab, Emactuzumab, Obinutuzumab - Lymphoma, Non-Hodgkin | Phase 1 | Withdrawn | Hoffmann-La Roche | 2018-03-14 | 2018-04-05 | |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2017-05-05 | 2024-03-13 |
| A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Emactuzumab, RO7009789 - Neoplasms | Phase 1 | Completed | Hoffmann-La Roche | 38 | 2016-05-09 | 2018-05-22 |
| A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors Atezolizumab, Emactuzumab - Solid Cancers | Phase 1 | Completed | Hoffmann-La Roche | 221 | 2015-01-19 | 2020-08-27 |
| A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors Paclitaxel, RO5509554 - Advanced Solid Tumors | Phase 1 | Completed | Hoffmann-La Roche | 217 | 2011-12-20 | 2018-03-16 |
Neoplasms (2) · Brenner Tumor (1) · Fallopian Tube Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Ovarian Neoplasms (1) · Synovitis (1) · Synovitis, Pigmented Villonodular (1)
Hoffmann-La Roche (5) · M.D. Anderson Cancer Center (1) · SynOx Therapeutics Limited (1)
United States (7) · France (5) · Belgium (4) · Spain (3) · Italy (2) · South Korea (2) · Australia (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · Czechia (1) · Denmark (1) · Germany (1) · Greece (1)
Anil K. Sood, MD (1) · Jean Y Blay, Prof, MD (1)
PMID 24898549, PMID 26179200, PMID 31114846, PMID 33097612, PMID 33161240, PMID 35577503, PMID 42473802
2014 (1), 2015 (1), 2017 (1), 2023 (1)